当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Lomustine and Bevacizumab in Progressive Glioblastoma
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-11-15 Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A. Brandes, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M. Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Andreas von Deimling, Vassilis Golfinopoulos, Jacoline C. Bromberg, Michael Platten, Martin Klein, Martin J. van den Bent
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2017-11-15 Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A. Brandes, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M. Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Andreas von Deimling, Vassilis Golfinopoulos, Jacoline C. Bromberg, Michael Platten, Martin Klein, Martin J. van den Bent
Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann–La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939; Eudra-CT number, 2010-023218-30.)
中文翻译：
洛莫斯汀和贝伐单抗在进行性胶质母细胞瘤中的作用
尽管在某种程度上延长了无进展生存期，但在进行性胶质母细胞瘤患者中，洛莫司汀联合贝伐单抗治疗并没有比洛莫司汀单独治疗具有生存优势。（由F. Hoffmann-La Roche和EORTC癌症研究基金提供无限制的教育资助； EORTC 26101 ClinicalTrials.gov号，NCT01290939； Eudra-CT号，2010-023218-30。）
更新日期：2017-11-16
中文翻译：
洛莫斯汀和贝伐单抗在进行性胶质母细胞瘤中的作用
尽管在某种程度上延长了无进展生存期，但在进行性胶质母细胞瘤患者中，洛莫司汀联合贝伐单抗治疗并没有比洛莫司汀单独治疗具有生存优势。（由F. Hoffmann-La Roche和EORTC癌症研究基金提供无限制的教育资助； EORTC 26101 ClinicalTrials.gov号，NCT01290939； Eudra-CT号，2010-023218-30。）
京公网安备 11010802027423号